NeoGenomics Inc
$ 9.65
-3.21%
24 Feb - close price
- Market Cap 1,252,688,000 USD
- Current Price $ 9.65
- High / Low $ 10.23 / 9.57
- Stock P/E N/A
- Book Value 6.49
- EPS -0.81
- Next Earning Report 2026-05-05
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.03 %
- ROE -0.12 %
- 52 Week High 13.74
- 52 Week Low 4.72
About
NeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States, Europe, and Asia. The company is headquartered in Fort Myers, Florida.
Analyst Target Price
$14.69
Quarterly Earnings
| Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-02-17 | 2025-10-28 | 2025-07-29 | 2025-04-28 | 2025-02-18 | 2024-11-05 | 2024-07-29 | 2024-04-30 | 2024-02-20 | 2023-11-06 | 2023-08-08 | 2023-05-08 |
| Reported EPS | 0.06 | 0.03 | 0.03 | -0.2035 | 0.04 | -0.1394 | 0.03 | -0.02 | 0.03 | -0.1473 | -0.05 | -0.09 |
| Estimated EPS | 0.04 | 0.02 | 0.02 | -0.005 | 0.0286 | 0.01 | -0.0023 | -0.05 | -0.02 | -0.07 | -0.11 | -0.15 |
| Surprise | 0.02 | 0.01 | 0.01 | -0.1985 | 0.0114 | -0.1494 | 0.0323 | 0.03 | 0.05 | -0.0773 | 0.06 | 0.06 |
| Surprise Percentage | 50% | 50% | 50% | -3970% | 39.8601% | -1494% | 1404.3478% | 60% | 250% | -110.4286% | 54.5455% | 40% |
Next Quarterly Earnings
| Mar 2026 | |
|---|---|
| Reported Date | 2026-05-05 |
| Fiscal Date Ending | 2026-03-31 |
| Estimated EPS | 0.0114 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: NEO
2026-02-24 14:52:03
NeoGenomics (NEO) reported fourth-quarter results that exceeded revenue and non-GAAP EPS expectations, driven by growth in next-generation sequencing and a strategic shift from lower-value testing. Despite beating some estimates, the market reacted negatively, with the stock declining. Analysts focused on key strategic initiatives such as RADAR ST reimbursement, the impact of exiting low-value contracts, LIMS system integration, the pharma segment outlook, and gross margin expansion plans for 2026.
2026-02-22 22:32:05
NeoGenomics has exercised its option to acquire the remaining stake in Inivata for $390 million, a move expected to position the company strongly in the liquid biopsy market. This acquisition gives NeoGenomics full ownership of InVisionFirst-Lung and the residual disease assay RaDaR, accelerating its presence in cancer diagnostics. Analysts believe NeoGenomics secured a favorable price due to the initial investment made last year.
2026-02-21 14:14:43
White Pine Capital LLC significantly increased its stake in NeoGenomics, Inc. (NASDAQ:NEO) by 394.3% in the third quarter, adding 110,735 shares to hold a total of 138,822 shares valued at approximately $1.07 million. Other institutional investors also adjusted their positions in the company, which is currently rated as a "Hold" by analysts with a consensus price target of $11.57. NeoGenomics, a cancer-focused genetic and molecular testing service provider, reported beating quarterly EPS and revenue estimates but remains unprofitable.
2026-02-20 09:35:00
NeoGenomics (NEO) has experienced a significant 22.8% decline over the past four weeks, but indicators suggest a potential trend reversal. Its Relative Strength Index (RSI) of 26.14 places it in oversold territory. Additionally, Wall Street analysts have shown strong agreement in raising earnings estimates for the current year, and the stock holds a Zacks Rank #2 (Buy).
2026-02-20 00:57:40
NeoGenomics, Inc. announced that its Chairman and Chief Executive Officer, Douglas VanOort, and Chief Strategy and Corporate Development Officer, Doug Brown, will present at the 20th Annual Needham Virtual Healthcare Conference on Thursday, April 15, 2021, at 11:00 am ET. The presentation will be webcast live on the investors section of the company's website. NeoGenomics specializes in cancer genetics testing and serves both physicians and pharmaceutical clients globally.
2026-02-19 21:27:37
Shares of NeoGenomics (NEO) fell over 10% after the oncology diagnostics company reported fourth-quarter results that beat expectations but issued a full-year 2026 forecast falling short of analyst predictions. Despite an 11% revenue growth in Q4 2025, the increased net loss for the full year 2025 and lower-than-anticipated 2026 guidance led to a negative market reaction. The company's stock has been highly volatile, with significant drops in the past year, and is currently trading 22.6% below its 52-week high.
